Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

PGNY - Progyny, Inc. So'nggi Yangiliklar | Finranks

Home

PGNY

P

Progyny, Inc. (PGNY)

NMS – Real vaqt narxi. Valyuta: USD

17.27

-0.52 (-2.92%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

17.27

0.00 (0.00%)

Bozordan keyin: Mar 27, 2026, 5:20 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Progyny, Inc. (PGNY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Progyny, Inc. (PGNY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Progyny, Inc. (PGNY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Barclays Raises Hims & Hers (HIMS) Target to $29 After Novo Deal Clears Legal Overhang — Canaccord Cuts Progyny (PGNY) on Cautious 2026 Outlook

Barclays Raises Hims & Hers (HIMS) Target to $29 After Novo Deal Clears Legal Overhang — Canaccord Cuts Progyny (PGNY) on Cautious 2026 Outlook

Two healthcare names are drawing fresh analyst attention this week as Wall Street recalibrates around a landmark GLP-1 truce and a fertility benefits company navigating a murky 2026 outlook.

Progyny, Inc. Executives to Participate in Upcoming Investor Conferences

Progyny, Inc. Executives to Participate in Upcoming Investor Conferences

NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that several members of its leadership team will participate in upcoming investor conferences in March, including the Leerink Partners Global Healthcare Conference, the Barclays Global Healthcare Conference, and the KeyBanc Capital Markets Healthcare Forum.

Progyny: Transitional Headwinds Hide An Undervalued Platform

Progyny: Transitional Headwinds Hide An Undervalued Platform

Progyny (PGNY) is undervalued at 9.3x forward P/E, with strong cash flow, expanding margins, and a resilient business model post-Amazon client loss. Headline FY26 growth appears muted (5.1%–9%) due to tough comps, but underlying growth excluding Amazon is 9.3–13.3%, with stable utilization rates near 1% and covered lives still expanding. PGNY's differentiated, outcome-focused platform, high retention, and buybacks (~15% share reduction in two years) support a robust medium-term investment case.

Progyny, Inc. (PGNY) Q4 2025 Earnings Call Transcript

Progyny, Inc. (PGNY) Q4 2025 Earnings Call Transcript

Progyny, Inc. (PGNY) Q4 2025 Earnings Call Transcript

Progyny (PGNY) Q4 Earnings and Revenues Surpass Estimates

Progyny (PGNY) Q4 Earnings and Revenues Surpass Estimates

Progyny (PGNY) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of $0.38 per share. This compares to earnings of $0.42 per share a year ago.

Compared to Estimates, Progyny (PGNY) Q4 Earnings: A Look at Key Metrics

Compared to Estimates, Progyny (PGNY) Q4 Earnings: A Look at Key Metrics

The headline numbers for Progyny (PGNY) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Videolar

No Data

There is no data to display

Press-relizlar

Progyny, Inc. Announces Fourth Quarter 2025 Results

Progyny, Inc. Announces Fourth Quarter 2025 Results

Reports Revenue of $318.4 Million, Reflecting Fourth Quarter Growth of 6.7% and 10% for the Full YearGenerated Record $210.2 Million in Full Year Operating Cash FlowReturned Value to Shareholders Through Repurchase of Approximately 6.5 Million Shares To Date Under Recent AuthorizationIssues Financial Guidance for 2026, Reflecting Tenth Consecutive Year of Revenue Growth

Progyny, Inc. Announces Details for Its Fourth Quarter and Full Year 2025 Results Report

Progyny, Inc. Announces Details for Its Fourth Quarter and Full Year 2025 Results Report

NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period and full year ended December 31, 2025, after the close of the market on Thursday, February 26, 2026.

Progyny to Discuss Updated Financial Expectations at Upcoming JP Morgan Healthcare Conference

Progyny to Discuss Updated Financial Expectations at Upcoming JP Morgan Healthcare Conference

NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a global leader in women's health and family building solutions, today announced that the Company is participating in the 44th Annual JP Morgan Healthcare Conference, where it intends to discuss its updated expectations for the quarter and year ending December 31, 2025. “As the fourth quarter progressed, we were pleased to see that member engagement has paced favorably as compared to the guidance we issued in November,” said Pete Anevski, Progyny's Chief Executive Officer.

New Men's Health Research from Progyny Challenges Conventional Beliefs about Fertility Knowledge and Action

New Men's Health Research from Progyny Challenges Conventional Beliefs about Fertility Knowledge and Action

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in family building solutions, today announced new men's health research exploring experiences and views on fertility. The findings shed light on how men in the U.S. view their role in the fertility journey and the barriers that prevent many from getting the care they need for successful conception.